Analyst rates Zura Bio a Hold: illustrative $1.45 fair value implies 17% upside, insufficient ahead of TibuSURE's H1 2027 Phase 2 readout.
Detailed price information for Zura Bio Ltd (ZURA-Q) from The Globe and Mail including charting and trades.
Detailed price information for Zura Bio Ltd (ZURA-Q) from The Globe and Mail including charting and trades.
Detailed price information for Zura Bio Ltd (ZURA-Q) from The Globe and Mail including charting and trades.
On August 11, Zura Bio (NASDAQ:ZURA) reported second-quarter results that landed on an unusual mix of good and bad news. The clinical-stage biotech finished enrolling two separate Phase 2 studies of its lead drug, tibulizumab, both ahead of their original targets, while a widening net loss showed just how much it costs to run them. […]
HENDERSON, Nev., August 31, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conference:
HENDERSON, Nev., August 21, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the Company granted inducement awards consisting of options to purchase up to 587,000 Class A Ordinary Shares (the "Options") to thirteen newly hired employees. These a
This is the newest page. Registered accounts read further back.